Dissecting mechanisms of innate and acquired immunity in myocarditis

Current Opinion in Cardiology

Volumn 18, Issue 3, 2003, Pages 175-181

  Ayach, Bilal ^a   Fuse, Koichi ^a   Martino, Tami ^a   Liu, Peter ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Acquired immunity; Coxsackievirus; Inflammation; Innate immunity; Mouse models; Myocarditis; Myosin

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; MYOSIN; NITRIC OXIDE; PLASMID DNA; TUMOR NECROSIS FACTOR; VIRUS RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOIMMUNE DISEASE; COXSACKIE VIRUS; DISEASE MODEL; EVALUATION; GENE OVEREXPRESSION; GENE TRANSFER; GENETIC MANIPULATION; HEART FAILURE; IMMUNE RESPONSE; IMMUNITY; IMMUNOMODULATION; INFLAMMATION; KNOCKOUT MOUSE; MOUSE; MOUSE STRAIN; MYOCARDITIS; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION; TECHNIQUE; TH1 CELL; TH2 CELL; TRANSGENIC MOUSE; TREATMENT PLANNING; VIRUS MYOCARDITIS;

ANIMALS; AUTOIMMUNE DISEASES; COXSACKIEVIRUS INFECTIONS; CYTOKINES; DISEASE MODELS, ANIMAL; IMMUNITY, ACTIVE; IMMUNITY, NATURAL; MICE; MYOCARDITIS; MYOSINS;

EID: 0043166465     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200305000-00001     Document Type: Review

References (78)

1. Frangogiannis NG, Smith CW, Entman ML: The inflammatory response in myocardial infarction. Cardiovasc Res 2002,c53:31-47.
2. Mann DL: Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002, 29:988-998.
3. Cohen J: The immunopathogenesis of sepsis. Nature 2002, 19-26:885-891.
4. Martino TA, Liu P, Petric M, et al.: Enteroviral myocarditis and dilated cardiomyopathy: A review of clinical and experimental studies. Human Enterovirus Infections. Edited by Rotbart HA. Washington D.C.: ASM Press; 1995:291-351.
5. Danesh J, Collins R, Appleby P, et al.: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease meta-analysis of prospective studies. JAMA 1998,279;1477-1482.
6. Irwin M, Mak S, Mann D, et al.: Tissue expression and immunolocalization of tumour necrosis factor-alpha in post infarction-dysfunctional myocardium. Circulation 1999, 99:1492-1498.
7. Nian M, Lee P, Liu P: Inflammation and cytokines in post-myocardial infarction remodeling. Circ Res 2003, in press.
8. Knuefermann P, Nemoto S, Baumgarten G, et al.: Cardiac inflammation and innate immunity in septic shock: is there a role for toll-like receptors? Chest 2002, 121:1329-1336.
9. Aretz HT: Myocarditis: the Dallas criteria. Hum Pathol 1987, 18:619-624.
10. Aretz HT, Billingham ME, Edwards WD, et al.: Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1987, 1:3-14.
11. Friman G, Wesslen L, Fohlman J, et al.: The epidemiology of infectious myocarditis, lymphocytic myocarditis and dilated cardiomyopathy. Eur Heart J 1995, 16:36-41.
12. O'Connell JB, Mason JW: Diagnosing and treating active myocarditis. West J Med 1989, 150:431-435.
13. Wee L, Liu P, Penn L, et al.: Persistence of viral genome into late stages of murine myocarditis detected by polymerase chain reaction. Circulation 1992, 86:1605-1614.
14. Tracy S, Wiegand V, McManus B, et al.: Molecular approaches to enteroviral diagnosis in idiopathic cardiomyopathy and myocarditis. J Am Coll Cardiol 1990, 15:1688-1694.
15. Kandolf R, Ameis D, Kirschner P, et al.: In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: an approach to the diagnosis of viral heart disease. Proc Natl Acad Sci U S A 1987, 84:6272-6276.
16. Liu P, Penninger J, Aitken K, et al.: The role of transgenic knockout models in defining the pathogenesis of viral heart disease. Eur Heart J 1995, 16:O25-O27.
17. Pummerer CL, Grassl G, Sailer M, et al.: Cardiac myosin-induced myocarditis: target recognition by autoreactive T cells requires prior activation of cardiac interstitial cells. Lab Invest 1996, 74:845-852.
18. Bachmaier K, Neu N, Yeung RS, et al.: Generation of humanized mice susceptible to peptide-induced inflammatory heart disease. Circulation 1999, 99:1885-1891.
19. Opavsky MA, Penninger J, Aitken K, et al: Susceptibility to myocarditis is dependent on the response of αβ T lymphocytes to coxsackieviral infection. Circ Res 1999, 85:551-558.
20. Liu P, Aitken K, Kong YY, et al.: Essential role for the tyrosine kinase p56lck in coxsackievirus B3 mediated heart disease. Nat Med 2000, 6:429-434.
21. Liu PP, Opavsky MA: Viral myocarditis: Receptors that bridge that immune with the cardiovascular systems. Circ Res 2000, 86:253-254.
22. Opavsky MA, Martino T, Rabinovitch M, et al.: Enhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis. J Clin Invest 2002, 109:1561-1569.
23. Diefenbach A, Schindler H, Donhauser N, et al.: Type 1 interferon (IFNalpha/beta) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite. Immunity 1998, 8:77-87.
24. Dangl J: Innate immunity. Plants just say NO to pathogens. Nature 1998, 394:525.
25. Rottenberg ME, Gigliotti Rothfuchs AC, Gigliotti D, et al.: Role of innate and adaptive immunity in the outcome of primary infection with Chlamydia pneumoniae, as analyzed in genetically modified mice. J Immunol 1999, 162:2829-2836.
26. Liu PP, Le J, Nian M: Nuclear factor-kappaB decoy: infiltrating the heart of the matter in inflammatory heart disease. Circ Res 2001, 9:850-2.
27. Wada H, Saito K, Kanda T, et al.: Tumor necrosis factor-alpha (TNF-alpha) plays a protective role in acute viralmyocarditis in mice: A study using mice lacking TNF-alpha. Circulation 2001, 103:743-749.
28. Shioi T, Matsumori A, Sasayama S: Persistent expression of of cytokine in the chronic stage of viral myocarditis in mice. Circulation 1996, 94:2930-2937.
29. Zaragoza C, Ocampo C, Saura M, et al.: The role of inducible nitric oxide synthase in the host response to Coxsackievirus myocarditis. Proc Natl Acad Sci U S A 1998, 95:2469-2474.
30. Matsuyama T, Kimura T, Kitagawa M, et al.: Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 1993, 75:83-97.
31. Gulick T, Chung MK, Pieper SJ, et al.: Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci U S A 1989, 86:6753-6757.
32. Yokoyama T, Vaca L, Rossen RD, et al.: Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993, 92:2303-2312.
33. Palmer JN, Hartogensis WE, Patten M, et al.: Interleukin-1 beta induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture. J Clin Invest 1995, 95:2555-2564.
34. Yokoyama T, Nakano M, Bednarczyk JL, et al.: Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997, 4:1247-1252.
35. Krown KA, Page MT, Nguyen C, et al.: Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996, 15:2854-2865.
36. Henke A, Huber S, Stelzner A, et al.: The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis. J Virol 1995, 69:6720-6728.
37. Kimura T, Nakayama K, Penninger J, et al.: Involvement of the IRF-1 transcription factor in antiviral responses to interferons. Science 1994, 24:1921-1924.
38. Huber SA, Stone JE, Wagner DH Jr, et al.: gamma delta+ T cells regulate major histocompatibility complex class II(IA and IE)-dependent susceptibility to coxsackievirus B3-induced autoimmune myocarditis. J Virol 1999, 73:5630-5636.
39. Cook DN, Beck MA, Coffman TM, et al.: Requirement of MIP-1 alpha for an inflammatory response to viral infection. Science 1995, 15:1583-1585.
40. Gebhard JR, Perry CM, Harkins S, et al.: Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance. Am J Pathol 1998, 153:417-428.
41. Chow LH, Beisel KW, McManus BM: Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viral pathogenesis of myocardial injury. Lab Invest 1992, 66:24-31.
42. Zoller J, Partridge T, Olsen I: Interactions between cardiomyocytes and lymphocytes in tissue culture: an in vitro model of inflammatory heart disease. J Mol Cell Cardiol 1994, 26:627-638.
43. Seko Y, Matsuda H, Kato K, et al.: Expression of intercellular adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackievirus B3. J Clin Invest 1993, 91:1327-1336.
44. Seko Y, Shinkai Y, Kawasaki A, et al.: Expression of perforin in infiltrating cells in murine hearts with acute myocarditis caused by coxsackievirus B3. Circulation 1991, 84:788-795.
45. Henke A, Nain M, Stelzner A, et al.: Induction of cytokine release from human monocytes by coxsackievirus infection. Eur Heart J 1991, 12:134-136.
46. Henke A, Mohr C, Sprenger H, et al.: Coxsackievirus B3-induced production of tumor necrosis factor-alpha, IL-1 beta, and IL-6 in human monocytes. J Immunol 1992, 1:2270-2277.
47. Henke A, Spengler HP, Stelzner A, et al.: Lipopolysaccharide suppresses cytokine release from coxsackie virus-infected human monocytes. Res Immunol 1992, 143:65-70.
48. Liu P, Martino T, Opavsky A, et al.: Myocarditis-balance between viral infection and immune response. Can J Cardiol 1996, 12:935-943.
49. Liu P, Mason J: Advances in the understanding of myocarditis. Circulation 2001, 104:1076-1082.
50. Sole MJ, Liu P: Viral myocarditis: Developing a paradigm for pathogenesis and treatment of dilated cardiomyopathy. J Am Coll Cardiol 1993, 22:99-105.
51. Hirasawa K, Tsutsui S, Takeda M, et al.: Depletion of Mac1-positive macrophages protects DBA/2 mice from encephalomyocarditis virus-induced myocarditis and diabetes. J Gen Virol 1996, 77:737-741.
52. Irie-Sasaki J, Sasaki T, Matsumoto W, et al.: CD45 is a JAK phosphatase and negatively regulates cytokine receptor signaling. Nature 2001, 409:349-354.
53. Neu N, Rose NR, Beisel KW, et al.: Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol 1987, 139:3630-3636.
54. Kodama M, Matsumoto Y, Fujiwara M, et al.: A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 1990, 57:250-262.
55. Yokoseki O, Suzuki J, Kitabayashi H, et al.: cis Element decoy against nuclear factor-kappaB attenuates development of experimental autoimmune myocarditis in rats. Circ Res 2001, 89:899-906.
56. Afanasyeva M, Wang Y, Kaya Z, et al.: Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-gamma-independent pathway. Circulation 2001, 104:3145-3151.
57. Watanabe K, Nakazawa M, Fuse K, et al.: Protection against autoimmune myocarditis by gene transfer of interleukin-10 by electroporation. Circulation 2001, 104:1098-1100.
58. Godney EK, Arizpe HM, Gaunti CJ: Characterization of the antibody response in vaccinated mice protected against Coxsackievirus B3-induced myocarditis. Viral Immunol 1987, 1:305-314.
59. Blay R, Simpson K, Leslie K, et al.: Coxsackievirus-induced disease. CD4+ cells initiate both myocarditis and pancreatitis in DBA/2 mice. Am J Pathol 1989, 135:899-907.
60. Lodge PA, Herzum M, Olszewski J, et al.: Coxsackievirus B-3 myocarditis. Acute and chronic forms of the disease caused by different immunopathogenic mechanisms. Am J Pathol 1987, 128:455-463.
61. Van Houten N, Huber SA: Genetics of Coxsackie B3 (CVB3) myocarditis. Eur Heart J 1991, 12:108-112.
62. Woodruff JF, Woodruff JJ: Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease. J Immunol 1974, 113:1726-1734.
63. Seko Y, Takahashi N, Azuma M, et al.: Expression of costimulatory molecule CD40 in murine heart with acute myocarditis and reduction of inflammation by treatment with anti-CD40L/B7-1 monoclonal antibodies. Circ Res 1998, 24:463-469.
64. Seko Y, Yagita H, Okumura K, et al.: Expression of vascular cell adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackievirus B3. J Pathol 1996, 180:450-454.
65. Gauntt CJ, Arizpe HM, Kung JT, et al.: Antimyocarditic activity of the guanine derivative BIOLF-70 in a coxsackievirus B3 murine model. Antimicrob Agents Chemother 1985, 27:184-191.
66. Hiraoka Y, Kishimoto C, Takada H, et al.: Effects of granulocyte colony-stimulating factor upon coxsackievirus B3 myocarditis in mice. Eur Heart J 1995, 16:1900-1906.
67. Huber SA, Polgar J, Schultheiss P, et al.: Augmentation of pathogenesis of coxsackievirus B3 infections in mice by exogenous administration of interleukin-1 and interleukin-2. J Virol 1994, 68:195-206.
68. Lane JR, Neumann DA, Lafond-Walker A, et al.: Interleukin 1 or tumor necrosis factor can promote Coxsackie B3-induced myocarditis in resistant B10.A mice. J Exp Med 1992, 1:1123-1129.
69. Matsumori A, Yamada T, Kawai C: Immunomodulating therapy in viral myocarditis: effects of tumour necrosis factor, interleukin 2 and anti-interleukin-2 receptor antibody in an animal model. Eur Heart J 1991, 12:203-205.
70. Kanda T, Sakamoto H, McManus BM, et al.: Interleukin-6 secreted from human myxoma reduces murine viral myocarditis. Life Sci 1996, 58:1705-1712.
71. Kanda T, Hirao Y, Oshima S, et al.: Interleukin-8 as a sensitive marker of unstable coronary artery disease. Am J Cardiol 1996, 1:304-307.
72. Shioi T, Matsumori A, Nishio R, et al.: Protective role of interleukin-12 in viral myocarditis. J Mol Cell Cardiol 1997, 29:2327-2334.
73. Gudvangen RJ, Duffey PS, Paque RE, et al.: Levamisole exacerbates coxsackievirus B3-induced murine myocarditis. Infect Immun 1983, 41:1157-1165.
74. Hiraoka Y, Kishimoto C, Takada H, et al.: Colony-stimulating factors and coxackievirus B3 myocarditis in mice: macrophage colony-stimulating factor suppresses acute myocarditis with increasing interferon-alpha. Am Heart J 1995, 130:1259-1264.
75. Ilback NG, Fohlman J, Slorach S, et al.: Effects of the immunomodulator LS 2616 on lymphocyte subpopulations in murine Coxsackievirus B3 myocarditis. J Immunol 1989, 1:3225-3228.
76. Ilback NG, Wesslen L, Pauksen K, et al.: Effects of the antiviral WIN 54954 and the immune modulator LS 2616 on cachectin/TNF and gamma-interferon responses during viral heart disease. Scand J Infect Dis Suppl 1993, 88:117-123.
77. Lane JR, Neumann DA, Lafond-Walker A, et al.: Role of IL-1 and tumor necrosis factor in coxsackie virus-induced autoimmune myocarditis. J Immunol 1993, 1:1682-1690.
78. Matsui S, Matsumori A, Matoba Y, et al.: Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production. J Clin Invest 1994, 94:1212-1217.